Six-month interim report (Q2) 2023
24 août 2023 01h30 HE
|
ALK Abello
ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and...
Six-month interim report (Q2) 2023
24 août 2023 01h30 HE
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by...
Release date of six-month interim report (Q2) 2023 for ALK and audio cast
18 août 2023 06h45 HE
|
ALK Abello
On Thursday, 24 August 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its six-month interim report (Q2) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm...
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2023 for ALK og webcast
18 août 2023 06h45 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2023 torsdag den 24. august 2023. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer og...
Administrerende direktør Carsten Hellmann fratræder ved udgangen af 2023. Peter Halling udpeget som hans efterfølger
19 juin 2023 02h40 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddeler i dag, at Carsten Hellmann fratræder som administrerende direktør ved udgangen af 2023. Han efterfølges af Peter Halling senest den 1. januar 2024. ...
President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor
19 juin 2023 02h40 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that Carsten Hellman will step down as President & CEO at the end of 2023. He will be succeed by Peter Halling no later than 1 January 2024. The...
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children
08 juin 2023 10h27 HE
|
ALK Abello
Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score (TCRS) of 22% compared to placebo (primary endpoint). Results were...
Stort, succesfuldt klinisk fase 3-studie når sit primære endemål og bekræfter potentialet af ALK's tabletvaccine mod husstøvmideallergi hos børn
08 juin 2023 10h27 HE
|
ALK Abello
Studiet mødte sit primære og alle væsentlige sekundære endemål med en forbedring i den totale kombinerede allergiske rhinitis-score (TCRS) på 22 % sammenlignet med placebo (primært endemål)....
Three-month interim report (Q1) 2023
09 mai 2023 01h20 HE
|
ALK Abello
Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit...
Three-month interim report (Q1) 2023
09 mai 2023 01h20 HE
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic...